Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Agio Rus is the Russian subsidiary of Agio Pharmaceuticals, an Indian-based pharmaceutical company. The company is primarily engaged in the marketing, distribution, and sales of a wide range of pharmaceutical products across the Russian Federation and the CIS region. Its portfolio includes various therapeutic categories such as gastroenterology, orthopedics, gynecology, and respiratory health, featuring well-known brands like Agisept and Agiflux. Agio Rus manages the regulatory registration process and commercial strategy for the parent company's generic and branded formulations. The company leverages the manufacturing strengths of its parent organization, which operates WHO-GMP certified facilities. By focusing on affordable and high-quality medications, Agio Rus has established a significant presence in the local retail and hospital sectors.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AGIO RUS.